Electro Optic Systems (EOS), the Australian firm behind a landmark high-energy laser contract, is planning a strategic move of its headquarters and listing to Europe within the year, its CEO reveals, aiming to embed itself at the heart of the continent's urgent defence modernisation drive.
ARK Invest's founder capitalized on recent market weakness to increase holdings in three of her flagship disruptive innovation picks, signaling continued conviction despite sector volatility.
Following the UK Prime Minister's visit to Beijing, China has agreed to slash tariffs on UK-produced whiskies from 10% to 5%, a move welcomed by the industry as a potential catalyst for growth in a key premium market.
As the Bank of Canada holds rates steady, speculative capital is sifting through junior resource stocks. We examine three micro-caps—a driller, an explorer, and an oil hopeful—navigating unique challenges and opportunities in early 2026.
Alphabet's stock surge, driven by its successful integration of AI, has investors weighing whether its current valuation still offers a compelling entry point for long-term growth.
American Express reported a 10.6% year-over-year revenue increase to $17.57 billion for the fourth quarter of 2025, yet missed Wall Street's sales expectations. Earnings per share of $3.53 met analyst consensus estimates.
A wave of insider selling at AutoZone over the past year, totaling $15 million, has drawn investor scrutiny. While the transactions occurred near current share prices, the scale of divestment compared to minimal buying prompts a closer look at the auto parts retailer's prospects.
President Trump's nomination of former Fed Governor Kevin Warsh to lead the central bank is seen as a pivotal test of its political independence, potentially aligning monetary policy more closely with White House objectives.
A fatal shark attack on a 13-year-old boy at a popular Brazilian beach has reignited concerns over coastal safety and led authorities to expand monitoring efforts along Pernambuco's coastline.
In a significant departure from its longstanding position, an Israeli military official has acknowledged a death toll in Gaza close to 70,000, aligning with figures long maintained by Palestinian health authorities. This admission follows over two years of war and persistent international scrutiny over casualty counts.
In its Q4 2025 letter, Greenlight Capital revealed a new position in dental distributor Henry Schein (HSIC), arguing the stock presents an opportunity for operational improvement and shareholder returns, despite recent underperformance.
A campaign-trail proposal to temporarily cap credit card interest at 10% could offer significant savings for millions of borrowers, but experts warn of potential unintended consequences for credit access and long-term financial health.
In its Q4 2025 letter, David Einhorn's Greenlight Capital revealed a new position in Antero Resources (AR), signaling a strategic move into the natural gas sector. The hedge fund's portfolio returned 8.5% for the quarter, outpacing the S&P 500.
South Africa has declared Israel's deputy ambassador persona non grata, giving him 72 hours to depart, citing "unacceptable" diplomatic violations and insulting social media posts targeting President Ramaphosa. The move escalates tensions already frayed by South Africa's genocide case against Israel at the UN's top court.
David Einhorn's Greenlight Capital has closed its position in insurer Brighthouse Financial following a sale agreement, detailing the move in its latest investor letter. The hedge fund reported solid quarterly returns but continues to trail the broader market.
In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.
Former Federal Reserve Governor Kevin Warsh, known for his hawkish stance but recently aligned with Trump's calls for lower rates, has been nominated by the former president to chair the Fed. The move, if confirmed, could test the institution's independence amid political pressure and an ongoing Justice Department probe.
As Eli Lilly prepares to report its Q4 and full-year 2025 results on February 4th, investors are weighing whether the pharmaceutical giant's premium valuation leaves room for a positive surprise, or if the stock is priced for perfection.
Newly launched oral weight-loss drug Wegovy from Novo Nordisk recorded more than 26,000 U.S. prescriptions in its second full week, signaling robust early demand as competition with Eli Lilly intensifies.
Consumer staples giant Church & Dwight (NYSE:CHD) reported fourth-quarter revenue in line with Wall Street expectations, though underlying organic sales showed signs of stagnation. The company's gross margin outperformance provided a bright spot, lifting shares post-earnings.
